IDO1 and neoplasm: Besides, ER signaling might activate IDO1, creating an “ER-IDO1 immune suppression axis” that strengthens tumor resistance to immunotherapy (Soliman et al., 2013; Fumagalli et al., 2016; Anurag et al., 2020).